Quality of life issues in elderly acute myeloid leukemia patients

Authors: Saini, Lalit; Alibhai, Shabbir MH; Brandwein, Joseph M

Source: Aging Health, 1 June 2011, vol. 7, no. 3, pp. 477-490(14)


Buy & download fulltext article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.


The median age of acute myeloid leukemia (AML) is 70 years. Treatment approaches include standard chemotherapy, palliative chemotherapy and investigational agents, depending upon disease biology and patient factors. In this article, we highlight the issues involved in the treatment of AML in older patients, focusing on the quality of life changes associated with each treatment modality at different stages of their disease course. We further discuss recent insights into the biological basis of quality of life changes, and examine potential ways to improve these through pharmacological and nonpharmacological means. Finally, we explore avenues for future research into the quality of life of the older AML patient.

Keywords: acute myeloid leukemia; chemotherapy; cytokine; elderly; exercise; nutrition; quality of life

Document Type: Research Article

DOI: http://dx.doi.org/10.2217/ahe.11.32

Affiliations: 1Department of Medical Oncology & Hematology, Princess Margaret Hospital, 610 University Avenue, Rm. 5––109, Toronto, ON M5G 2M9, Canada

Publication date: June 1, 2011

Related content


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page